Search

Your search keyword '"Lorea Aguinaga"' showing total 3 results
Start Over Author "Lorea Aguinaga" Publication Type Academic Journals
3 results on '"Lorea Aguinaga"'

2. Characteristics and mid-term follow-up of COVID-19 patients with hematological diseases: a retrospective study from a French tertiary care hospital

Author

Nicolas Vallet, Sylvie Chevret, Linda Feghoul, Lorea Aguinaga, Louise Bondeelle, Eleonore Kaphan, Rémi Bertinchamp, Juliette Soret, Camille Villesuzanne, Nathalie De Castro, Marie Sebert, David Boutboul, Etienne Lengline, Jean-Jacques Tudesq, Florence Rabian, Lionel Adès, Alienor Xhaard, Roberta Di Blasi, Emmanuel Raffoux, Lionel Galicier, Jérôme Le Goff, Constance Delaugerre, Anne Bergeron, Stéphanie Harel, and Saint-Louis CORE group

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2021
Full Text
View/download PDF

3. Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes’ army

Author

Ricardo García-Muñoz, María-Josefa Nájera, Jesús Feliu, Judith Antón-Remírez, Enrique Ramalle-Gómara, Raquel Marín-Gorricho, Raisa Peralta, Elena Gutiérrez-Gamarra, Jessica Nuñez-Rodriguez, Ricardo Zafra-Morales, Lorea Aguinaga, María-Jose Nebot-Villacampa, Prisma-Monserrat Hernandez-Pérez, Giovanna Farfán-Quiroga, Carlos Panizo, and Elena Domínguez-Garrido

Subjects
ADCC, chronic lymphocytic leukemia, follicular lymphoma, GA101, ibrutinib, NK cells, Medicine, Medicine (General), R5-920
Abstract

Aim: To analyze the effects of subcutaneous or intravenous rituximab + lymphokine-activated killer cells, obinutuzumab or ibrutinib on natural killer (NK) cell levels in chronic lymphocytic leukemia and follicular lymphoma patients. Patients & methods: The distribution of peripheral blood NK cells of 31 patients was analyzed by flow cytometry. Results: We detected a decrease of NK cells in peripheral blood below normal range after obinutuzumab treatment. During maintenance treatment with subcutaneous rituximab, an NK cell reduction was less pronounced than after intravenous rituximab treatment, despite lymphokine-activated killer cell infusions. Conclusion: After one dose of obinutuzumab, each NK cell in peripheral blood destroys 25 leukemic cells.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results